Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
Authors:
Open Access
- 20 May 2021
- journal article
- research article
- Published by Springer Nature in npj Breast Cancer
- Vol. 7 (1) , 1-10
Abstract
The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study that evaluated progression-free survival (PFS) of GV compared with capecitabine in gpNMB-overexpressing TNBC. Patients who had previously received anthracycline and taxane-based therapy were randomized 2:1 to receive, GV (1.88 mg/kg IV q21 days) or capecitabine (2500 mg/m2 PO daily d1–14 q21 days). The primary endpoint was RECIST 1.1 PFS per independent, blinded central review. In all, 327 patients were randomized to GV (213 treated) or capecitabine (92 treated). Median PFS was 2.9 months for GV vs. 2.8 months for capecitabine. The most common grade ≥3 toxicities for GV were neutropenia, rash, and leukopenia, and for capecitabine were fatigue, diarrhea, and palmar-plantar erythrodysesthesia. The study did not meet the primary endpoint of improved PFS over capecitabine or demonstrate a relative risk/benefit improvement over capecitabine.Keywords
Funding Information
- Celldex Therapeutics
This publication has 33 references indexed in Scilit:
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast CancerJournal of Clinical Oncology, 2014
- Drug Resistance in Cancer: An OverviewCancers, 2014
- Breast cancer brain metastases responding to primary systemic therapy with T-DM1Journal of Neuro-Oncology, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Beyond taxanes: the next generation of microtubule-targeting agentsBreast Cancer Research and Treatment, 2011
- Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast CancerClinical Cancer Research, 2010
- Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?Oncology, 2010
- Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.Cancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Osteoactivin Promotes Breast Cancer Metastasis to BoneMolecular Cancer Research, 2007